http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3676403-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e974c8a148aa6bf505c7e049484889e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2018-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03dc4707dadee13aedec039f3fa7b4e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d68e01e8d3c84e34d2ea1124b005a1fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfc8e49ca70a4df74c853d7b11c4cdb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e796a23481c1b6a0eee14e01108a4c2 |
| publicationDate | 2020-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3676403-A1 |
| titleOfInvention | Gene expression and assessment of risk of developing toxicity following cell therapy |
| abstract | The present invention relates to methods for determining whether a subject has a risk of developing toxicity, for example neurotoxicity, following the administration of a therapy, such as an immunotherapy or a cell therapy, for example a cell therapy. chimeric antigen receptor (T-C R) T cell based on the expression, in a sample taken from the subject, of one or more genes or gene products that are associated and / or correlated with a risk to develop toxicity following the administration of the therapy. In some aspects, the sample is a sample taken from the subject prior to administration of the therapy. The invention also relates to methods of treating a subject suffering from a disease or condition, such as acute lymphoblastic leukemia (ALL), according to a particular treatment regimen, in some cases involving the administration of immunotherapy or cell therapy, based on the evaluation of the risk of developing toxicity following the administration of the therapy. The invention also relates to reagents and kits for the implementation of said methods. |
| priorityDate | 2017-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2230.